Relationship Between Anti-Müllerian Hormone and In Vitro Fertilization-Embryo Transfer in Clinical Pregnancy

Xing Yu Sun¹, Yun Zhu Lan², Shuang Liu², Xiao Ping Long³, Xi Guang Mao¹,³* and Ling Liu²*

¹ Department of Obstetrics and Gynecology, The Affiliated Hospital of Southwest Medical University, Luzhou, China,² Department of Reproductive Center, The Affiliated Hospital of Southwest Medical University, Luzhou, China, ³ Department of Obstetrics and Gynecology, Affiliated Traditional Chinese Medicine Hospital, Southwest Medical University, Luzhou, China

Objectives: To retrospectively analyze the correlation between anti-Müllerian hormone (AMH) and the number of oocytes obtained by controlled ovarian hyperstimulation (COH) in women of different ages and explore the factors affecting in vitro fertilization and embryo transfer (IVF-ET) in clinical pregnancy of infertile women to provide evidence for infertile women to choose assisted reproduction strategies.

Methods: Infertile women who received IVF-ET or intracytoplasmic sperm injection and embryo transfer (ICSI-ET) treatment in the reproductive center of XX hospital between October 2018 and September 2019 were included. Patient data on medical records, age, body mass index (BMI), years of infertility, basic follicle-stimulating hormone (FSH), basic luteinizing hormone (LH), basic estradiol (E2), anti-Müllerian hormone level (AMH), antral follicle count (AFC), gonadotropins (Gn) medication days, Gn dosage, endometrial thickness on transplantation day, the number of retrieved oocytes, the number of mature oocytes obtained, the number of embryos transferred, clinical pregnancy status, etc., were collected.

Results: A total of 314 patients were enrolled in this study, with an average age of 31.0 ± 4.5 years. The infertility period ranged from 0–21 years. The AMH level showed a downward trend with increasing age. Overall, the AMH level of women of all ages was positively correlated with the number of retrieved oocytes (r = 0.335, p < 0.001). The AMH level of women between 22 and 28 years old was positively correlated with the number of retrieved oocytes (r = 0.164, p < 0.061) but it was not statistically significant. Similarly, the AMH level of women aged 29–35 and 36–43 was positively correlated with the number of retrieved oocytes (r = 0.356, p < 0.001; r = 0.461, p < 0.001). The average age of the pregnant group (30.6 ± 4.4 years) was lower than that of the non-pregnant group (32.2 ± 4.6 years) (p < 0.001). The number of oocytes obtained (9.8 ± 4.5) and the number of embryos transferred (1.9 ± 0.4) in the pregnant group was significantly higher than that in the non-pregnant group (9.2 ± 4.5; 1.7 ± 0.5); the difference was statistically significant. The multivariate logistic regression model showed that age (OR = 0.574 95% CI: 0.350–0.940),
AMH (OR = 1.430 95% CI: 1.130–1.820) and the number of oocytes obtained (OR = 1.360 95% CI: 1.030–1.790) were factors affecting clinical pregnancy.

**Conclusion:** We found that the level of AMH in infertile women decreased with age and the number of oocytes obtained in infertile women was positively correlated with AMH. Moreover, the number of oocytes and embryo transferred in the pregnant group was significantly higher than those in the non-pregnant group. Furthermore, age, AMH and the number of oocytes affected the clinical pregnancy.

**Keywords:** anti-Müllerian hormone, pregnancy, in vitro fertilization-embryo transfer, assisted reproductive technologies, infertile women

**INTRODUCTION**

In recent years, the fertility problem of infertile women has become a major challenge for reproductive doctors. Assisted reproductive technologies (ARTs) are an important alternative to solve the problem of infertile women. However, the success of pregnancy depends on various factors, including gamete quality, uterine receptivity and immune factors. Among them, the key factors affecting infertile women are the decrease in the number and quality of oocytes.

At present, indicators for evaluating ovarian reserve function include age, follicle-stimulating hormone (FSH), anti-Müllerian hormone (AMH), and antral follicle count (AFC). Among them, AMH is a member of the transforming growth factor β (TGF-β) superfamily. It is a dimer glycoprotein formed by disulfide bonds. In women, antral follicles and small follicles secrete AMH, which has the effect of promoting growth and differentiation. The level of AMH is positively correlated with the number of antral follicles and small follicles in the ovary. Studies have shown that AMH can not only reflect the number of antral follicles but also the quality of oocytes (1, 2). Generally, it is believed that AMH is maintained throughout the menstrual cycle and it is stable (3–5). Therefore, AMH is considered to be the best indicator to evaluate ovarian reserve. The role of AMH in ART has always been one of the research hotspots in the field of assisted reproduction. Controlled ovarian hyperstimulation (COH) is a key part of assisted reproductive technology and plays a vital role in the success or failure of treatment. Several clinical studies have shown that patients with low AMH levels have a higher cancellation rate of oocytes retrieval cycles because of low ovarian response (6–9). Some researchers also pointed out that AMH levels are correlated with the number of oocytes retrieved, fertilization rate, number of embryos available and clinical pregnancy (10–12). However, the relationship between AMH and the number of oocytes retrieved in infertile women at different ages is yet to be studied.

Herein, we analyze the correlation between AMH and the number of retrieved oocytes obtained by COH in women of different ages and explores the factors affecting in vitro fertilization and embryo transfer (IVF-ET) in clinical pregnancy of infertile women to provide a basis for infertile women to choosing assisted reproduction strategies.

**METHODS**

**Patient Enrollment and Data Collection**

This is a retrospective study of infertile women who received IVF-ET or intracytoplasmic sperm injection and embryo transfer ICSI-ET treatment in the reproductive center of XX hospital from October 2018 and September 2019. Estimate sample size based on “multi-stage random sampling survey”. The sample size was estimated to obtain the prevalence within 1 of the true value at 1 level of significance. This kind of sample design has an impact, called design effect on sampling variability. As a result of this impact, the obtained sample size was multiplied by 1.5 and the outcome was taken as the final sample size. Patients who (1) underwent IVF-ET or ICSI-ET treatment; (2) promoted ovulation through long, short or antagonist programs; and (3) had bilateral ovaries based on transvaginal color Doppler ultrasound were included. Patients with (1) metabolic abnormalities or endocrine diseases (such as polycystic ovary syndrome, diabetes, abnormal thyroid function, Cushing syndrome, etc.); (2) chromosomal abnormalities in either spouse; (3) a history of ovarian surgery; (4) infectious diseases, autoimmune diseases, allergic diseases, tumors, hepatitis and other diseases; (5) a history of thrombosis or family history; and (6) endometriosis were excluded.

Patient data on medical records, age, body mass index (BMI), years of infertility, basic FSH, basic luteinizing hormone (LH), basic estradiol (E₂), AMH level, AFC, gonadotropins (Gn) medication days, Gn dosage, endometrial thickness (mm) on transplantation day, the number of oocytes obtained, the number of mature oocytes obtained, the number of embryos transferred and clinical pregnancy status etc. were collected.

**Clinical Indicators**

**AMH Test**

The blood samples of all patients were stored at -20°C and tested by an enzyme-linked immunoassay kit (ELISA, AMH quantitative test kit, Guangzhou Kangrun Biotechnology Co., Ltd.). The minimum detectable AMH concentration was 0.06 ng/ml, the relevant coefficient (r) ≥0.9900, the relative deviation of the measurement results was within 10% and the coefficient of variation (CV) ≤10%.
Judgment of Oocyte Maturity
According to the development and morphological evaluation of the oocyte, the oocyte is divided into three classes, mature oocyte (MII stage): the endogenous foaming of the oocyte cytoplasm disappears and the first polar body can be seen in the perivitelline space; the intermediate mature oocyte (MI phase): the endogenous foaming of the oocyte cytoplasm disappears and the perivitelline space is not seen first in the polar body; immature oocytes (GV stage): germinal follicles can be seen in the cytoplasm. Based on the oocyte maturity criterion, the number of mature oocytes obtained in this study was that obtained at the MII stage (13).

Embryo Quality Judgment
According to embryo development speed and morphological score, embryos are divided into 4 Grades, Grade I: uniform blastomere size, homogeneous and transparent cytoplasm, no debris; Grade II: uniform blastomere size, with debris <20%; Grade III: unequal size of blastomeres, with more fragments (20–50%); Grade IV: unequal size of blastomeres, fragments >50%. Based on these embryo quality determination standards, Grades I and II embryos were high-quality embryos in our laboratory.

Rate of retrieved mature oocytes = number of retrieved mature oocytes/number of retrieved oocytes (%)
Clinical pregnancy rate = number of clinical pregnancy cycles/number of hyperstimulation cycles (%)

Statistical Analysis
All data were reported as number and percentage, while continuous data were reported as mean ± standard deviation (SD). We used the chi-square ($\chi^2$) test or the Fisher’s exact test to compare categorical data. Mann-Whitney-Wilcoxon test was applied to compare nonnormally continuous variables. Pearson correlation and multiple linear regression were used to analyze the correlation between AMH level and the number of oocytes obtained. Logistic regression models were used to evaluate the influencing factors of clinical pregnancy. All statistical analyses were performed using SPSS 23.0 (SPSS Inc, Chicago, Ill). A value of $p < 0.05$ was considered statistically significant.

RESULTS
Patient Characteristics
A total of 314 patients aged between 22 and 43 years old were selected, with an average age of 31.0 ± 4.5 years old. The infertility period was between 0 and 21 years, with an average age of 4.4 years. Detailed patient characteristics are shown in Table 1.

Comparison of Different Parameters of Patients in Different Age Groups
In this study, the ages of the female patients were divided into three groups: 22–28, 29–35, and 36–43 years old. The duration of infertility varied among the age groups (Table 2). The average duration of infertility increased with an increase in age. Women between the ages of 36 and 43 had the longest duration of infertility, with an average of about 5.7 years. The total dosage of basal FSH and Gn increased with an increase in age, while basal LH, basic E₂, basic prolactin (PRL), basic testosterone (T), AMH, and the number of oocytes harvested and the number of MII retrieved oocytes all showed a decreasing trend. Age (woman and man), infertility years, basic PRL, and AMH showed significant differences in different age groups.

AMH Levels in Different Age Groups
Figure 1 shows the average and SD of AMH levels for women of different ages. There was a significant difference in the AMH levels among the three age groups. In addition, AMH levels decreased with increasing age (Table 3). AMH levels of women aged 22–28 were significantly higher than those aged 29–35. However, AMH levels of women aged 29–35 were significantly higher than those aged 36–43. Similarly, AMH levels of women aged 22–28 were significantly higher than those aged 36–43.

Correlation Between the AMH Level and the Number of Oocytes Obtained
Figure 2 and Table 4 show the correlation between the AMH level and the number of oocytes obtained in women of different ages. Overall, in women of all ages, the level of AMH was positively correlated with the number of oocytes retrieved ($r = 0.335, p < 0.001; \text{Figure 2A}$). The level of AMH was positively correlated with the number of retrieved oocytes in women aged 22–28 ($r = 0.164, p < 0.061; \text{Figure 2B}$) but not statistically significant due to the small sample size and sampling errors. In addition, the level of AMH was positively correlated with the number of oocytes obtained in women aged 29–35 ($r = 0.356, p < 0.001; \text{Figure 2C}$). Moreover, there was a positive correlation...
between the level of AMH and the number of oocytes obtained in women aged 36–43 (r = 0.461, p < 0.001; Figure 2D).

Comparison of Factors Influencing IVF-ET Clinical Pregnancy in Infertile Women

Age, number of years of infertility, BMI, basic FSH, basic LH, basic E₂, basic PRL, basic T, basic progesterone (P), AMH, intimal thickness, number of oocytes harvested, and total Gn dosage of pregnant and non-pregnant patients were compared. The total number of Gn days, the number of embryos transferred, the number of MII oocytes and the rate of mature oocytes were statistically significant in the female age, the number of oocytes obtained and the number of embryos transferred between the two groups. The average age of women in the pregnant group and the non-pregnant group was 30.6 ± 4.4 years and 32.2 ± 4.6 years, respectively. The average age of the pregnant group was lower than that of the non-pregnant group (p < 0.001). The number of oocytes obtained and the number of embryos transferred was significantly higher in the pregnant group than in the non-pregnant group and the difference was statistically significant (Table 5).

Comparison of the Basic Information and Cycle Status of Infertile Women With Different AMH Levels

AMH levels were classified into low (<2.74), medium (2.74–5.66) and high (≥5.66) according to tertiles. Age (woman and man), basic LH, the number of oocytes obtained, the total amount of Gn, the number of embryos transferred, the number of MII oocytes, basic FSH, basic PRL, and the thickness of the intima were significantly different among the three AMH groups. As shown in Table 6, the female and male patients in the high AMH group were the youngest, 29.40 ± 4.0 and 31.6 ± 4.8 years old, respectively, while the patients in the low AMH group were the oldest, 32.60 ± 4.5 and 34.9 ± 6.5 years old, respectively. The high AMH group had a lower basal FSH level of 8.2 ± 2.5 mIU/ml, while the low AMH level group had the highest basal LH level of 9.9 ± 4.1 mIU/ml. LH and the number of oocytes obtained, the number of embryos transferred and the number of MII oocytes

**TABLE 2 | Baseline data of different age groups of women.**

| Clinical parameters | 22–28 (n = 90) | 29–35 (n = 169) | 36–43 (n = 55) | P     |
|---------------------|---------------|----------------|--------------|-------|
| The age of women    | 25.8 ± 1.9    | 31.4 ± 1.9     | 38.1 ± 2.1   | <0.001|
| The age of men      | 28.2 ± 3.3    | 33.6 ± 4.3     | 39.5 ± 6.3   | <0.001|
| Years of infertility| 3.3 ± 1.8     | 4.8 ± 3.2      | 5.7 ± 5.4    | 0.001 |
| BMI (kg/m²)         | 22.4 ± 4.1    | 22.7 ± 3.7     | 22.5 ± 6.0   | 0.83  |
| Basic FSH (mIU/ml)  | 6.5 ± 3.0     | 9.2 ± 3.7      | 8.6 ± 2.9    | 0.094 |
| LH (mIU/ml)         | 4.4 ± 4.8     | 4.1 ± 3.6      | 4.0 ± 5.2    | 0.736 |
| Basic E₂ (pg/ml)    | 228.6 ± 569.8 | 171.7 ± 425.4  | 141.4 ± 444.1 | 0.581 |
| PRL                 | 16.9 ± 17.6   | 13.4 ± 7.3     | 12.9 ± 6.2   | 0.018 |
| Basic T             | 55.1 ± 25.0   | 48.7 ± 23.4    | 42.9 ± 17.7  | 0.072 |
| Basic P             | 1.7 ± 3.6     | 1.8 ± 4.8      | 1.7 ± 3.7    | 0.993 |
| AMH (ng/ml)         | 6.6 ± 4.4     | 5.2 ± 4.4      | 3.4 ± 2.8    | 0.039 |
| Intimal thickness (mm) | 6.5 ± 2.5     | 6.5 ± 2.7      | 6.4 ± 2.8    | 0.999 |
| Number of eggs obtained (pieces) | 9.9 ± 4.1 | 9.5 ± 4.9      | 7.8 ± 3.3    | 0.795 |
| The total of Gn     | 2373.2 ± 1002.7 | 2632.4 ± 933.0 | 3105.0 ± 903.5 | 0.071 |
| The total days of Gn | 11.3 ± 2.3    | 11.1 ± 1.9     | 11.0 ± 2.2   | 0.48  |
| Number of embryos transferred (pieces) | 1.6 ± 0.5 | 1.7 ± 0.5      | 1.7 ± 0.8    | 0.099 |
| Number of MII (pieces) | 9.2 ± 4.0     | 8.5 ± 4.7      | 7.3 ± 3.4    | 0.421 |
| Rate of obtaining mature eggs (%) | 92.3 ± 0.1 | 90.0 ± 0.2     | 92.6 ± 0.1   | 0.212 |
| Ending              |                 |               |              |       |
| Clinical pregnancy  | 30 (33.3%)     | 61 (36.1%)     | 14 (25.5%)   | 0.988 |
| Biochemical pregnancy | 11 (12.2%)   | 21 (12.4%)     | 8 (14.5%)    |       |
| Not pregnant        | 48 (53.3%)     | 83 (49.1%)     | 31 (56.4%)   |       |

**TABLE 3 | AMH levels in women of different ages.**

| Age (years) | Number | The level of AMH (ng/ml) |
|-------------|--------|--------------------------|
| 22–28       | 90     | 6.6 ± 4.4<sup>A</sup>   |
| 29–35       | 169    | 5.2 ± 4.4<sup>B</sup>   |
| 36–43       | 55     | 3.4 ± 2.8<sup>C</sup>   |

AMH, Anti-Müllerian hormone.
of the high AMH group were higher. PRL of the middle-level AMH group was the highest, 16.52 ± 16.38. The Gn dosage of the high AMH group was the lowest, 1998.0 ± 726.9 (Table 6).

**Multivariate Logistic Regression Analysis**
Statistically significant variables were included in the multivariate logistic regression model. The results showed that age (OR = 0.574 95% CI: 0.350–0.940, \( p = 0.027 \)), AMH (OR = 1.430 95% CI: 1.130–1.820, \( p = 0.003 \)) and the number of oocytes obtained (OR = 1.360 95% CI: 1.030–1.790, \( p = 0.032 \)) were independent factors influencing clinical pregnancy (Table 7).

**DISCUSSION**
In recent years, due to low ovarian reserve, infertile women have faced problems such as low pregnancy rate and live birth rate, which has become a major challenge for reproductive physicians. The number and quality of women’s oocytes decrease with age but the fertility of women of the same age varies greatly, hence, the accuracy of predicting pregnancy outcome by age only is low.
The level of AMH remains relatively constant during the menstrual cycle and can reflect ovarian reserve. Therefore, the application of AMH in advanced-age ARTs has become one of the research hotspots among local and international scholars. A total of 314 advanced-age infertile women were included in this study and the AMH variation range of different age groups of infertile women was established. The correlation between AMH and the number of oocytes obtained in different age groups was analyzed, and the independent influence of clinical pregnancy was explored. This should help to guide elderly infertile women seeking IVF treatment.

Because of the lack of a standardized method to measure AMH levels and variation in AMH levels caused by different methods (6, 14), it is necessary to establish a reference range for AMH for different age groups. The patients included in this study were aged 22–43 years old, with an average age of 31.0 ± 4.5 years. The patients were divided into three groups according to their ages. The levels of AMH of patients of different age groups were described and compared. It was found that the average AMH level increased with age. The levels of AMH exhibited a decreasing trend and varied widely in each age group. This is consistent with the results of previous studies (15, 16). AMH is considered the most reliable indicator of ovarian reserve. AMH can reflect the number of antral follicles and is directly proportional to the number of oocytes obtained in hyperstimulation (17, 18). Studies have shown that patients with the same AMH level of different ages have a lower number of ovulation-stimulation than patients in the elderly group, which indicates that age is one of the key factors in the study of ovarian stimulation effects (19). This study compared the correlation between the level of AMH and the number of oocytes obtained in infertile women of different ages and found that the level of AMH in infertile women was positively correlated with the number of oocytes obtained. A further comparison of the levels of AMH in different age groups showed that the levels of AMH in women aged 29–43 were linearly correlated with the number of oocytes harvested, with a statistical significance, which is consistent with findings from previous research (20–22).

We also compared the pregnant and the non-pregnant groups and found that there were statistical differences in the age, the number of oocytes retrieved and the number of embryos transferred between the two groups, suggesting that these three variables could be factors affecting clinical pregnancy. After classifying the levels of AMH in advanced-age infertile women into three groups (low, medium and high), we found that age, basic LH, number of oocytes harvested, total Gn dosage, number of embryos transferred, number of MII oocytes, basic FSH, basic PRL and intimal thickness were significantly different among the groups. However, our findings are different from a

### TABLE 6 | Comparison of data of different AMH levels.

| Clinical parameters | AMH < 2.74 (n = 104) | 2.74 ≤ AMH < 5.66 (n = 105) | AMH ≥ 5.66 (n = 105) | P |
|---------------------|----------------------|-----------------------------|---------------------|---|
| The age of women    | 32.6 ± 4.5           | 31.0 ± 4.4                  | 29.4 ± 4.0          | <0.001 |
| The age of men      | 34.9 ± 6.5           | 32.8 ± 5.5                  | 31.6 ± 4.8          | <0.001 |
| Years of infertility| 4.6 ± 3.9            | 4.7 ± 3.7                   | 3.9 ± 2.7           | 0.197  |
| BMI (kg/m²)         | 22.6 ± 3.3           | 22.0 ± 4.2                  | 23.1 ± 5.1          | 0.178  |
| Basic FSH (mIU/ml)  | 9.9 ± 4.1            | 9.1 ± 3.3                   | 8.2 ± 2.5           | 0.001  |
| LH (mIU/ml)         | 3.2 ± 1.9            | 3.5 ± 2.3                   | 5.8 ± 6.4           | <0.001 |
| Basic E₂ (pg/ml)    | 142.3 ± 367.6        | 261.6 ± 622.1               | 143.8 ± 380.9       | 0.112  |
| PRL                 | 13.0 ± 6.0           | 16.52 ± 16.38               | 13.5 ± 8.3          | 0.048  |
| Basic T             | 50.1 ± 26.2          | 46.5 ± 23.1                 | 51.9 ± 20.0         | 0.227  |
| Basic P             | 1.3 ± 3.3            | 2.0 ± 5.0                   | 1.9 ± 4.4           | 0.495  |
| AMH (ng/ml)         | 1.5 ± 0.7            | 4.0 ± 0.8                   | 10.3 ± 3.7          | <0.001 |
| Intimal thickness (mm) | 7.0 ± 2.9        | 6.5 ± 2.7                   | 5.9 ± 2.4           | 0.017  |
| Number of eggs obtained (pieces) | 6.9 ± 3.9 | 9.9 ± 4.0                  | 11.1 ± 4.4          | <0.001 |
| The total of Gn     | 3088.8 ± 969.4       | 2840.0 ± 865.7              | 1998.0 ± 726.9      | 0.001  |
| The total days of Gn | 11.1 ± 2.5          | 11.1 ± 1.9                  | 11.2 ± 1.9          | 0.949  |
| Number of embryos transferred (pieces) | 1.7 ± 0.5 | 1.7 ± 0.5                   | 1.8 ± 0.5           | <0.001 |
| Number of MII (pieces) | 6.2 ± 3.7          | 9.1 ± 4.0                   | 10.2 ± 4.3          | <0.001 |
| Rate of obtaining mature eggs % | 89.3 ± 0.2 | 90.6 ± 0.1                  | 92.2 ± 0.1          | 0.343  |
| Ending               | ![Clinical parameters](https://i.imgur.com/3QZc.png) | ![Clinical parameters](https://i.imgur.com/3QZc.png) | ![Clinical parameters](https://i.imgur.com/3QZc.png) | ![Clinical parameters](https://i.imgur.com/3QZc.png) |

BMI, body mass index; FSH, follicle stimulating hormone; LH, luteinizing hormone E₂, estradiol; AMH, Anti-Mullerian hormone; Gn, gonadotropins.

### TABLE 7 | Logistic regression analysis of clinical pregnancy and abortion factors.

| Clinical parameters | OR   | 95% CI     | P    |
|---------------------|------|------------|------|
| The age of women    | 0.574| 0.350–0.940| 0.027|
| The age of men      | 1.007| 0.945–1.073| 0.827|
| Basic FSH (mIU/ml)  | 1.042| 1.067–1.124| 0.278|
| Basic LH (mIU/ml)   | 0.987| 0.928–1.050| 0.681|
| Basic PRL           | 1.003| 0.983–1.025| 0.749|
| AMH (ng/ml)         | 1.43 | 1.130–1.820| 0.003|
| Intimal thickness (mm)| 1.065| 0.973–1.165| 0.173|
| Number of eggs obtained (pieces) | 1.36 | 1.030–1.790| 0.032|
| The total of Gn     | 1.000–1.000| 0.731|
| Number of embryos transferred (pieces) | 1.40 | 0.846–2.348| 0.195|
| Number of MII (pieces) | 1.000–1.000| 0.999|

BMI, body mass index; FSH, follicle stimulating hormone; LH, luteinizing hormone E₂, estradiol; AMH, Anti-Mullerian hormone; Gn, gonadotropins.
German study (8) perhaps due to the age of the included population; age affects the outcome of assisted pregnancy.

A European study of women over 40 years of age found that compared with the non-pregnant group, patients in the pregnant group had lower ages and higher levels of AFC and AMH, but considered that AMH was related to those over 40 years of age.

The pregnancy outcome in women based on IVF-ET is not relevant (23). Some researchers believe that AMH can predict the clinical pregnancy of IVF in elderly women. Lee analyzed the relationship between the level of AMH and clinical pregnancy in women older than 40 years and reported that AMH is an independent factor that can predict pregnancy (24). The present study further compared the clinical data of the pregnant and the non-pregnant groups and the data of patients with different AMH levels. There were differences in factors such as age, AMH and the number of oocytes obtained between the groups. After incorporating them into the multivariate logistic regression model, age, AMH and the number of oocytes obtained were independent factors in clinical pregnancy. Two European and American studies also found that age and AMH were independent factors predicting IVF pregnancy outcome, which is consistent with our results (25, 26).

This study had some strengths and weaknesses. First, to reduce selection bias, this study only included patients in the first IVF cycle. In addition, patients were further grouped by age to reduce the heterogeneity caused by age changes and the relationship between the number of oocytes obtained and AMH was analyzed by age. However, this study had a small sample size and is a retrospective study with many confounding factors. Furthermore, some variables were not considered in the study.

CONCLUSIONS

We found that the level of AMH in infertile women decreased with age and the number of oocytes obtained in infertile women aged 29–43 was positively correlated with AMH. Age, AMH and the number of oocytes obtained were independent factors influencing clinical pregnancy. Moreover, the number of oocytes and embryo transferred in the pregnant group was significantly higher than that in the non-pregnant group. Furthermore, the clinical pregnancy was affected by age, AMH and number of oocytes. To the best of our knowledge, this is the first study to retrospectively analyze the correlation between AMH and the number of oocytes obtained by COH in women of different ages. This information could help understand the relationship between AMH and IVF-ET in clinical pregnancy.

DATA AVAILABILITY STATEMENT

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

ETHICS STATEMENT

The studies involving human participants were reviewed and approved by Ethics Committee of Affiliated Hospital of Southwest Medical University. Written informed consent for participation was not required for this study in accordance with the national legislation and the institutional requirements.

AUTHOR CONTRIBUTIONS

XS and YL conceived and designed the study. SL and XL collected patient data, XM and LL reviewed and edited the manuscript. All authors contributed to the article and approved the submitted version.

FUNDING

The study was supported by the project of Luzhou science and Technology Bureau (no. 16188) and Science Foundation of Southwest Medical University (no. 2016217).

ACKNOWLEDGMENTS

We thank the participants of the survey and all staff members involved in this study for their painstaking efforts in conducting the data collection.

REFERENCES

1. Iliodromiti S, Kelsey TW, Wu O, Anderson RA, Nelson SM. The predictive accuracy of anti-Müllerian hormone for live birth after assisted conception: a systematic review and meta-analysis of the literature. *Hum Reprod Update* (2014) 20(4):560–70. doi: 10.1093/humupd/dmu003
2. Pilgaard F, Grymerup AG, Løssl K, Bungum L, Pinborg A. The use of anti-Müllerian hormone for controlled ovarian stimulation in assisted reproductive technology, fertility assessment and counseling. *Acta Obstet Gynecol Scand* (2018) 97(9):1105–13. doi: 10.1111/aogs.13334
3. La Marca A, Stabile G, Artenisio AC, Volpe A. Serum anti-Müllerian hormone throughout the human menstrual cycle. *Hum Reprod* (2006) 21(12):3103–7. doi: 10.1093/humrep/del291
4. Massarotti C, La Pica V, Sozzi F, Scaruffi P, Remorgida V, Anserini F. Influence of age on response to controlled ovarian stimulation in women with low levels of serum anti-Müllerian hormone. *Gynecol Endocrinol* (2020) 9:1–5. doi: 10.1080/09513590.2020.1737668
5. Younis JS, Iskander R, Fauser BCJM, Izhaki I. Does an association exist between menstrual cycle length within the normal range and ovarian reserve biomarkers during the reproductive years? A systematic review and meta-analysis. *Hum Reprod Update* (2020) 26(6):904–28. doi: 10.1093/humupd/dmaa013
6. Ebner T, Sommergruber M, Moser M, Schreibl O, Schreier-Lechner E, Tews E. Basal level of the anti-Müllerian hormone is associated with oocyte quality in stimulated cycles. *Hum Reprod* (2006) 21(8):2022–6. doi: 10.1093/humrep/del127
7. Lamazou F, Fuchs F, Grynberg M, Gallot V, Herzog E, Fanchin R, et al. Cancellation of IVF-ET cycles: poor prognosis, poor responder, or variability of the response? Controlled ovarian hyperstimulation? An analysis of 142 cancellations. J Gynecol Obstet Biol Reprod (Paris) (2012) 41(1):41–7. doi: 10.1016/j.jgyn.2011.06.001

8. Gomez R, Schorsch M, Hahn T, Henke A, Hoffmann I, Seufert T, et al. The influence of AMH on IVF success. Arch Gynecol Obstet (2016) 293(3):667–73. doi: 10.1007/s00404-015-0198

9. Rotterdam ESHRE/ASRM-Sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod (2004) 19(1):41–7. doi: 10.1093/humrep/deh098

10. La Marca A, Giuliani S, Tirelli A, Bertucci E, Marsella T, Xella S, et al. Anti-Müllerian hormone measurement on any day of the menstrual cycle strongly predicts ovarian response in assisted reproductive technology. Hum Reprod (2007) 22(3):766–71. doi: 10.1093/humrep/del421

11. Kastora SL, Triantafyllidou O, Kolovos G, Kastoras A, Sigalos G, Vlahos N. Combinational approach of retrospective clinical evidence and transcriptomics highlight AMH superiority to FSH, as successful ICSI outcome predictor. J Assist Reprod Genet (2020) 37(7):1623–35. doi: 10.1007/s10815-020-01802-w

12. Xu H, Shi L, Feng G, Xiao Z, Chen L, Li R, et al. An Ovarian Reserve Assessment Model Based on Anti-MMüllerian Hormone Levels, Follicle-Stimulating Hormone Levels, and Age: Retrospective Cohort Study. J Med Internet Res (2020) 22(9):e19096. doi: 10.2196/19096

13. Lin YC, Chang SY, Lan KC, Huang HW, Chang CY, Tsai MY, et al. Human oocyte maturity in vivo determines the outcome of blastocyst development in vitro. J Assist Reprod Genet (2003) 20(12):506–12. doi: 10.1023/b:jarg.0000013651.37866.0c

14. Seifer DB, Baker VL, Leader B. Age-specific serum anti-Müllerian hormone values for 17,120 women presenting to fertility centers within the United States. Fertil Steril (2011) 95(2):747–50. doi: 10.1016/j.fertnstert.2010.10.011

15. Cui Y, Shi Y, Cui L, Han T, Gao X, Chen ZL. Age-specific serum antimullerian hormone levels in women with and without polycystic ovary syndrome. Fertil Steril (2014) 102(1):230–6.e2. doi: 10.1016/j.fertnstert.2014.03.032

16. Masse V, Ferrari P, Boucoiran I, Delotte J, Isnard V, Bongain A. Normal serum concentrations of anti-müllerian hormone in a population of fertile women in their first trimester of pregnancy. Hum Reprod (2011) 26(12):3431–6. doi: 10.1093/humrep/det320

17. Anckaert E, Smitz J, Schiettecatte J, Klein BM, Arce JC. The value of anti-Müllerian hormone measurement in the long GnRH agonist protocol: association with ovarian response and gonadotrophin-dose adjustments. Hum Reprod (2012) 27(6):1829–39. doi: 10.1093/humrep/des101

18. Patrelli TS, Gizzo S, Sianesi N, Levati L, Pezzuto A, Ferrari B, et al. Anti-Müllerian hormone serum values and ovarian reserve: can it predict a decrease in fertility after ovarian stimulation by ART cycles? PloS One (2012) 7(9):e44571. doi: 10.1371/journal.pone.0044571

19. Reinichman DE, Goldschlag D, Rosenwaks Z. Value of antimullerian hormone as a prognostic indicator of in vitro fertilization outcome. Fertil Steril (2014) 101(4):1012–8. doi: 10.1016/j.fertnstert.2013.12.039

20. Borges E, Braga DPAF, Setti A, Figueira RC, Iaconelli A Jr. The predictive value of serum concentrations of anti-Müllerian hormone for oocyte quality, fertilization, and implantation. JBRASSist Reprod (2017) 21(3):176–82. doi: 10.5935/1518-0557.20170035

21. Nelson SM, Yates RW, Fleming R. Serum anti-Müllerian hormone and FSH: prediction of live birth and extremes of response in stimulated cycles–implications for individualization of therapy. Hum Reprod (Oxford England) (2007) 22(9):2414–21. doi: 10.1093/humrep/dem204

22. Ng EH, Tang OS, Ho PC. The significance of the number of antral follicles before stimulation in predicting ovarian responses in an IVF programme. Hum Reprod (Oxford England) (2000) 15(9):1937–42. doi: 10.1093/humrep/15.9.1937

23. Broer SL, Broekmans FJ, Laven JS, Fauser BC. Anti-Müllerian hormone: ovarian reserve testing and its potential clinical implications. Hum Reprod Update (2014) 20(5):688–701. doi: 10.1093/humupd/dmu020

24. Lee RK, Wu FS, Lin MH, Lin SY, Hwu YM. The predictability of serum anti-Müllerian level in IVF/ICSI outcomes for patients of advanced reproductive age. Reprod Biol Endocrinol (2011) 9:115. doi: 10.1186/1477-7827-9-115

25. GREicher N, WEGhofer A, BARad DH. Anti-Müllerian hormone (AMH) defines, independent of age, low versus good live-birth chances in women with severely diminished ovarian reserve. Fertil Steril (2010) 94(7):2824–7. doi: 10.1016/j.fertnstert.2010.04.067

26. La Marca A, Nelson SM, Sighinolfi G, Manno M, Baraldi E, Roli L, et al. Anti-Müllerian hormone-based prediction model for live birth in assisted reproduction. Reprod Biomed Online (2011) 22(4):341–9. doi: 10.1016/j.rbmo.2010.11.005

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.